The Urological Disorders Therapeutics to 2016 Increasing Awareness and Aging Population will Drive
09/24/2010

Aarkstore announce a new report " The Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive Benign Prostatic Hyperplasia and Urinary Incontinence Markets" through its vast collection of market research report.

Online PR News – 24-September-2010 – – Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Summary

Therapeutic Analysis report, “Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For more information please contact:
http://www.aarkstore.com/reports/The-Urological-Disorders-Therapeutics-to-2016-Increasing-Awareness-and-Aging-Population-will-Drive-Benign-Prostatic-Hyperplasia-and-Urinary-Incontinence-Markets-61584.html

From:AarkstoreEnterprise
Contact:jessica
Email:jessica@aarkstore.com
Contact:+918149852585
URL:www.aarkstore.com/